FDA-Approved MedicationUpdated November 2026

Wegovy Guide

Wegovy is the brand-name formulation of semaglutide, approved for long-term weight management, for lowering cardiovascular risk, and (since August 2025) for treating noncirrhotic MASH with liver fibrosis. Developed by Novo Nordisk, it is available as a once-weekly subcutaneous injection (0.25–2.4 mg, or up to 7.2 mg Wegovy HD for weight reduction) and, since December 2025, a once-daily oral tablet, 1.5–25 mg, carrying the adult weight reduction and cardiovascular risk reduction indications.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

At a Glance

Wegovy at a glance
Generic NameSemaglutide
Brand NamesWegovy
FDA StatusFDA-approved for chronic weight management in adults with obesity or overweight with comorbidity (June 2021); cardiovascular risk reduction in adults with established CVD (March 2024); weight reduction in pediatric patients aged 12+ (December 2022); noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults (August 2025, accelerated approval); and an oral tablet form for cardiovascular risk reduction or weight reduction in adults (December 2025), alongside the original injection[1]
Approval DateJune 4, 2021[1]

How does Wegovy work?

Wegovy mimics the GLP-1 hormone to signal fullness to the brain, slow stomach emptying, and reduce overall caloric intake. The injection reaches a maintenance dose of 1.7–2.4 mg weekly (up to 7.2 mg for weight reduction if more loss is needed); the 2026-added oral tablet reaches a 25 mg once-daily maintenance dose through its own 90-day titration — both deliver the same active ingredient, semaglutide, just via a different route and schedule.[2]

Dosing Schedule — Injection

Wegovy uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–40.25mg/week
Weeks 5–80.5mg/week
Weeks 9–121.0mg/week
Weeks 13–161.7mg/week
Week 17+1.7–2.4mg/week (maintenance; varies by indication, up to 7.2mg for weight reduction)

Dosing Schedule — Tablet (approved December 2025)

Days 1–301.5mg/day
Days 31–604mg/day
Days 61–909mg/day
Day 91+25mg/day (maintenance)

What side effects does Wegovy cause?

Common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache, fatigue. The pattern over time: worst while the dose is being stepped up, largely settled by week 4 to 8. Serious (rare): pancreatitis, gallstones, kidney injury, heart rate increase. The suicidal behavior and ideation section was removed from the label in February 2026 after large studies found no increase.[1][2]

Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].

Clinical Trial Results

Two trials carry Wegovy. STEP-1 put mean body-weight loss at 14.9% over 68 weeks — roughly 34 lbs — against 2.4% on placebo. SELECT (N=17,604) then took obese patients with established CVD and cut major adverse cardiovascular events by 20%.[2][3][4]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where can you get Wegovy?

Sellers in our register that will dispense semaglutide, or a compounded version of it, after an online consultation — shipped to your door.

8.8/ 10
Verified partner

altRX

Best for: compounded semaglutide from $89/month at the same price at every dose

★★★★☆8.8/10

Editorial score · methodology

$1,579/mo
BrandSemaglutideLegitScript Verified
Get StartedRead full altRX review →
8.1/ 10
Verified partner

Sesame Care

Best for: oral orforglipron alongside the injectables

★★★★☆8.1/10

Editorial score · methodology

$149/mo+ care fee
BrandSemaglutide
Get StartedRead full Sesame Care review →
7.9/ 10
Verified partner

RxSpan MD

Best for: knowing which pharmacy fills the vial: it names Belmar Pharmacy

★★★★☆7.9/10

Editorial score · methodology

$1,349/mo
BrandSemaglutideGlutathioneNAD+SermorelinLegitScript Verified
Get StartedRead full RxSpan MD review →
7.9/ 10
Verified partner

ShedRx

Best for: oral orforglipron alongside the injectables

★★★★☆7.9/10

Editorial score · methodology

$149/mo+ membership
BrandSemaglutideGHK-CuGlutathioneNAD+
Get StartedRead full ShedRx review →
7.4/ 10
Verified partner

AgelessRx

Best for: microdosed compounded GLP-1s from a longevity clinic, or brand Wegovy at manufacturer pricing plus monitoring

★★★★☆7.4/10

Editorial score · methodology

$414/mo
BrandSemaglutideGHK-CuGlutathioneNAD+
Get StartedRead full AgelessRx review →
7.4/ 10
Verified partner

Wellorithm

Best for: compounded semaglutide at a flat $247 every 28 days, any dose

★★★★☆7.4/10

Editorial score · methodology

$899/moprepaid
BrandSemaglutide
Get StartedRead full Wellorithm review →

58 sellers in the register publish a price; the lowest starts at $100 a month, checked November 2026. What each one charges to start, cheapest at the top. Compounded semaglutide from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[5], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[6]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[7]. What you actually pay moves with your dose and with whatever promotion happens to be running.

Starting Wegovy price per seller, cheapest first. Prices in USD per month; checked November 2026.
ProviderStarting PriceLink
Oak$100/moVisit
Amazon One Medical$149/mo + visit feeVisit
Heally$149/moVisit
Healthspan$149/mo + membershipVisit
Hims$149/mo + membershipVisit
Imbue Health$149/mo + membershipVisit
Intermountain Health On-Demand Weight Loss$149/mo + consult feeVisit
Knownwell$149/mo + visit feeVisit
médetone$149/mo + membershipVisit
Mochi Health$149/mo + membershipVisit
Show all 58 Wegovy sellers
Wegovy sellers 11 to 58, cheapest first. Prices in USD per month.
NovoCare Pharmacy$149/moVisit
PreventiveMD$149/moVisit
Ro$149/mo + membershipVisit
Sesame Care$149/mo + care feeVisit
ShedRx$149/mo + membershipVisit
Walgreens Weight Management$149/mo + visit feeVisit
WeightWatchers Clinic$149/mo + membershipVisit
ZipHealth$149/mo + feesVisit
Aspire Health$199/mo + care feeVisit
Found$199/mo + membershipVisit
GOAL.MD$244/moVisit
Alloy$248/moVisit
Phoenix NP$248/moVisit
SkinnyRx$248/moVisit
Maximus$249.99/moVisit
Healthicare$268.68/moVisit
Good Girl Rx$297/moVisit
LifeMD$298/moVisit
Rex MD$349/moVisit
WePeptideRx$399/moVisit
AgelessRx$414/moVisit
Näky$424/mo + membershipVisit
Klinic$499/moVisit
Pallas Health$499/moVisit
Wellorithm$899/mo, prepaidVisit
Synergy Rx$947/moVisit
Vital Edge$990/moVisit
Josie$1,199/moVisit
RxSpan MD$1,349/moVisit
Trimrose$1,349/moVisit
Corsica Health$1,499/moVisit
RxION Health$1,499/moVisit
Astra$1,500/moVisit
Immortals$1,550/mo, prepaidVisit
altRX$1,579/moVisit
DudeMeds$1,585/moVisit
HeliMeds$1,599/mo, prepaidVisit
Effecty$1,600/moVisit
AlyveRx$1,695/moVisit
GobyMeds$1,695/moVisit
Elara Women's Wellness$1,697/moVisit
Eve$1,699/moVisit
Layla$1,699/moVisit
Tomorrow$1,699/moVisit
OrderlyMeds$1,839/moVisit
BiltRx$1,849/moVisit
myRocky$1,869/mo + program feeVisit
Concierge MD LA$1,999/moVisit

Short verdict pages setting Wegovy against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

See all drug-vs-drug verdicts.

The trials that produced the Wegovy label, taken endpoint by endpoint, with the figures read off the source.

STEP-1
STEP-1 is the reason a weight-loss drug became a household subject. Semaglutide 2.4 mg against placebo in 1,961 people carrying obesity but not diabetes produced −14.9% body weight at 68 weeks, against −2.4% on placebo, and 86.4% of the treated group lost at least 5%. It established the Wegovy dose and the modern benchmark for what a GLP-1 can do. It is also the most quoted figure in this market, which makes two details matter: what was in the syringe, and who was in the trial.
Phase 3 · N=1,961
SELECT
SELECT enrolled 17,604 adults aged 45 and over who had existing cardiovascular disease and a BMI of at least 27 but no diabetes, then followed them for a mean 39.8 months on semaglutide 2.4 mg or placebo. Three-point MACE occurred in 6.5% against 8.0%, a 20% relative reduction. It is the largest trial in this section and the one with the most consequence, because it moved semaglutide from a drug that changes how people look to a drug shown to prevent heart attacks and strokes.
Phase 3 · N=17,604
STEP-4
STEP-4 is the trial that ended the idea of a GLP-1 course. Every participant reached semaglutide 2.4 mg during a 20-week run-in, then was randomized two-to-one to continue or move to placebo for 48 more weeks. Those who continued lost a further 7.9% of body weight. Those who switched regained 6.9%. Same people, same starting point, one variable. It is the shortest route to understanding why this is chronic therapy, and it is the trial to read before signing a twelve-month prepay or planning an exit.
Phase 3a · N=803
STEP-2
STEP-2 is to STEP-1 what SURMOUNT-2 is to SURMOUNT-1: the same drug and design, in people who also have type 2 diabetes. Semaglutide 2.4 mg produced −9.6% body weight at 68 weeks against −3.4% on placebo, alongside a 1.6-point HbA1c reduction. Against STEP-1's −14.9%, the five-point gap is the price of the diabetes, and −9.6% is the number a reader with diabetes should be working from.
Phase 3 · N=1,210

Questions people actually asked about Wegovy in named subreddits, each answered from the published trial data.

One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.

Wegovy Dose Ladder Cheat Sheet: Shot and Tablet
Wegovy is no longer one product with one ladder. There is a weekly injection that climbs in four steps, a high-dose 7.2 mg strength above the usual maintenance, and a once-daily tablet with a completely separate 90-day schedule and its own rules about food. This page holds all of it against the current label, including the missed-dose arithmetic people most often get wrong.
6 min read
GLP-1 Injection Sites: Rotation, Technique and the Lump to Avoid
Every weekly GLP-1 permits the same three injection sites and each label wants the spot rotated. The reason is a lump called lipohypertrophy — thickened fat that soaks up the drug at an unpredictable rate. When absorption becomes erratic so does appetite suppression, and a stalled month gets blamed on the dose when the cause is a favorite square inch of belly.
4 min read
Saxenda Dose Ladder Cheat Sheet: the Three-Day Trap
Saxenda is the odd one out: liraglutide, injected every day, climbing to its full dose in five weeks rather than sixteen. The short half-life that makes daily dosing necessary also creates the rule most people do not know about — three consecutive missed days and you restart the whole ladder from 0.6 mg, because your tolerance for it is already gone.
5 min read
Switching Between GLP-1s: Why You Start at the Bottom Again
Switching is common (a formulary changes, side effects bite, or you reach the top of a ladder with weight still to lose), and no label tells you how to do it. The rule that surprises people is that you go back to the bottom even though you have been on a GLP-1 for a year. Tolerating one of these drugs does not buy you tolerance of another, because they do not act on the same receptors.
5 min read

The peer-reviewed studies on Wegovy and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.

The 10 Semaglutide Weight-Loss Trials That Matter (2026)
Semaglutide has been tested more thoroughly for weight than any drug before it, and the ten trials below are the ones that changed something: the dose we use, the label it carries, what happens when you stop, and whether it does anything beyond the scale. Each entry gives the PMID, the design, and the figure that mattered.
10 ranked papers
The 10 Liver Trials: What GLP-1s Do to MASH (2026)
Liver disease has become one of the most active areas for these drugs, and the arc runs from a small biopsy trial in 2016 to a phase 3 result likely to change the standard of care. Included deliberately: the trial in cirrhosis that missed its endpoint, because knowing where a drug stops working is more useful than another positive result.
10 ranked papers
GLP-1s and Bone: 10 Studies on a Risk Nobody Has Measured Properly
Losing weight quickly costs bone density no matter how it is done. Whether these drugs add anything on top of that is unsettled: one randomized trial says they protect bone, another says the drug alone loses more density than exercise alone. The fracture meta-analyses are reassuring and underpowered, and no trial has followed a non-diabetic obesity population long enough to matter.
10 ranked papers
GLP-1s for Teenagers: the 10 Trials Behind the Approvals (2026)
Adolescent obesity had almost nothing approved for it a decade ago. Three trials changed that (STEP TEENS, SCALE Teens and ELLIPSE), and this list covers them alongside the analyses that shaped how they are prescribed and the bariatric-surgery results that were, until recently, the only real option for severe cases.
10 ranked papers

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

503A vs 503B Compounding Pharmacies: Who Oversees Your Compounded GLP-1
A 503A pharmacy compounds per patient under a state board. A 503B outsourcing facility registers with FDA, follows CGMP, is inspected and must report adverse events. What each means for compounded GLP-1s, and how to check yours.
10 min read12 citations
The Head-to-Head, and What It Settles
751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.
7 min read3 citations
Many People Never Reach the Dose
Only 58% of people starting semaglutide reached the recommended maintenance dose after four weeks, and 21% stayed on the starting dose. More than half of oral semaglutide starters stopped altogether.
6 min read1 citation
Switching Between GLP-1 Drugs
No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.
5 min read3 citations
Does Your GLP-1 Wear Off Before the Next Dose?
Half of each dose is still present when the next one is due. The label puts semaglutide's elimination half-life at roughly seven days, tirzepatide's at about five. That is a slope, not a cliff.
6 min read2 citations
GLP-1 Drugs and Type 1 Diabetes: The Label Says Unevaluated. Three Trials Disagree.
36% of people with type 1 diabetes and obesity hit a composite of time-in-range, low-glucose safety and 5% weight loss, against 0% on placebo. Total daily insulin fell about a third in a second trial.
7 min read9 citations

Frequently Asked Questions

FDA-approved for chronic weight management in adults with obesity or overweight with comorbidity (June 2021); cardiovascular risk reduction in adults with established CVD (March 2024); weight reduction in pediatric patients aged 12+ (December 2022); noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults (August 2025, accelerated approval); and an oral tablet form for cardiovascular risk reduction or weight reduction in adults (December 2025), alongside the original injection
What you pay for Wegovy turns on who is selling it and in what form. Uninsured, the branded product runs roughly $1,000 to $1,600 a month; compounded versions through telehealth sellers usually land between $129 and $400. The table above carries the current figures from our register. Before you commit, check whether a manufacturer savings program applies to you.
Common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache, fatigue. The pattern over time: worst while the dose is being stepped up, largely settled by week 4 to 8. Serious (rare): pancreatitis, gallstones, kidney injury, heart rate increase. The suicidal behavior and ideation section was removed from the label in February 2026 after large studies found no increase.
Wegovy is prescription-only, so someone licensed has to write it — your own doctor, an endocrinologist, or one of the telehealth sellers above. For compounded versions the telehealth route is usually both quicker and cheaper out of pocket than a traditional pharmacy.
Sources & methodology — as of November 2026
  1. 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.
  4. 4.SELECT Trial — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (Lincoff AM et al.)— New England Journal of Medicine.PMID: 37952131.
  5. 5.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  6. 6.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  7. 7.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary

The words sellers use, defined. Tap any term.